Novartis, the Swiss pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has granted priority review for its licensing application of panobinostat, a histone deacetylase inhibitor, as a new treatment for myeloma. The submission is based on the results of the PANORAMA-1 trial involving panobinostat in combination with Velcade® and dexamethasone in relapsed and/or refractory patients who had received at least one prior line of treatment. A decision is expected within the next six months.

Read the full article ┬╗